ALGN vs. DXCM, HQY, HSIC, MEDP, QTRX, CAH, HAE, MCK, RMD, and WST
Should you be buying Align Technology stock or one of its competitors? The main competitors of Align Technology include DexCom (DXCM), HealthEquity (HQY), Henry Schein (HSIC), Medpace (MEDP), Quanterix (QTRX), Cardinal Health (CAH), Haemonetics (HAE), McKesson (MCK), ResMed (RMD), and West Pharmaceutical Services (WST). These companies are all part of the "medical" sector.
Align Technology vs. Its Competitors
Align Technology (NASDAQ:ALGN) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.
Align Technology currently has a consensus target price of $241.25, indicating a potential upside of 22.51%. DexCom has a consensus target price of $98.50, indicating a potential upside of 19.06%. Given Align Technology's higher possible upside, equities research analysts clearly believe Align Technology is more favorable than DexCom.
In the previous week, DexCom had 10 more articles in the media than Align Technology. MarketBeat recorded 31 mentions for DexCom and 21 mentions for Align Technology. Align Technology's average media sentiment score of 1.22 beat DexCom's score of 1.08 indicating that Align Technology is being referred to more favorably in the media.
DexCom has a net margin of 12.90% compared to Align Technology's net margin of 10.29%. DexCom's return on equity of 30.05% beat Align Technology's return on equity.
88.4% of Align Technology shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.7% of Align Technology shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Align Technology has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.
DexCom has higher revenue and earnings than Align Technology. Align Technology is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Summary
DexCom beats Align Technology on 12 of the 17 factors compared between the two stocks.
Get Align Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Align Technology Competitors List
Related Companies and Tools
This page (NASDAQ:ALGN) was last updated on 7/5/2025 by MarketBeat.com Staff
Free ALGN Stock Alerts